Overview of possible side effects of cancelizumab

Concizumab (trade name Alhemo) is a tissue factor pathway inhibitor (TFPI) antagonist, mainly used for patients with hemophilia A (congenital factor VIII with FVIII inhibitors) span>deficiency) or for treatment of hemophiliaB (congenital factorIXdeficiency) with a FIX inhibitor.

However, as a biological agent, cancelizumab may also produce some side effects during use. One of the most common side effects of cancelizumab is an injection site reaction, which may appear as bruising, redness, bleeding, or itching. These reactions are usually mild and resolve without special treatment.

Cancelizumab may cause allergic reactions, including redness, rash, hives, itching, and abdominal pain. In rare cases, severe allergic reactions such as shortness of breath, wheezing, tightness in the chest, pale, cold skin, rapid heartbeat, and dizziness due to low blood pressure may occur. If any signs or symptoms of a serious allergic reaction occur, stop using canezizumab immediately and seek emergency medical help.

Cancelizumab may cause blood clots to form in blood vessels, increasing the risk of thromboembolic events. This risk may be increased particularly if breakthrough bleeding is treated with high or frequent doses of factor products or bypass drugs, or if you have certain medical conditions. Therefore, patients should be closely monitored for signs and symptoms of blood clots while taking cancezumab, such as skin swelling, warmth, pain or redness, shortness of breath, or severe chest pain.

In addition to the above-mentioned side effects, cancelizumab may also cause other adverse reactions, such as cardiovascular system symptoms, hair loss, proteinuria, etc. However, the incidence of these side effects is relatively low and varies from person to person.

It should be noted that due to the short time on the market, comprehensive information about its side effects is still accumulating. Therefore, before using cancelizumab, patients should fully understand its possible side effects and use it rationally under the guidance of a doctor. At the same time, Concezizumab is not currently on the market in China, and patients cannot directly buy the drug domestically. For specific drug information, they can consult local hospitals and pharmacies for more information.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761315s000lbl.pdf